- Home
- NSC vs REGN Comparison
NSC vs REGN Comparison
Compare NSC & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSC
- REGN
- Stock Information
- Founded
- NSC 1980
- REGN 1988
- Country
- NSC United States
- REGN United States
- Employees
- NSC N/A
- REGN N/A
- Industry
- NSC Railroads
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- NSC Industrials
- REGN Health Care
- Exchange
- NSC Nasdaq
- REGN Nasdaq
- Market Cap
- NSC 67.3B
- REGN 59.5B
- IPO Year
- NSC N/A
- REGN 1991
- Fundamental
- Price
- NSC $287.18
- REGN $673.40
- Analyst Decision
- NSC Buy
- REGN Buy
- Analyst Count
- NSC 21
- REGN 21
- Target Price
- NSC $297.40
- REGN $782.62
- AVG Volume (30 Days)
- NSC 1.1M
- REGN 955.1K
- Earning Date
- NSC 10-23-2025
- REGN 10-28-2025
- Dividend Yield
- NSC 1.88%
- REGN 0.52%
- EPS Growth
- NSC 22.97
- REGN 2.88
- EPS
- NSC 13.11
- REGN 41.59
- Revenue
- NSC $12,230,000,000.00
- REGN $14,247,800,000.00
- Revenue This Year
- NSC $2.14
- REGN $1.34
- Revenue Next Year
- NSC $3.25
- REGN $5.23
- P/E Ratio
- NSC $21.93
- REGN $16.22
- Revenue Growth
- NSC 0.48
- REGN 2.89
- 52 Week Low
- NSC $201.63
- REGN $476.49
- 52 Week High
- NSC $302.24
- REGN $834.42
- Technical
- Relative Strength Index (RSI)
- NSC 53.40
- REGN 71.45
- Support Level
- NSC $279.81
- REGN $640.99
- Resistance Level
- NSC $284.68
- REGN $664.00
- Average True Range (ATR)
- NSC 3.78
- REGN 19.49
- MACD
- NSC 0.41
- REGN 4.21
- Stochastic Oscillator
- NSC 79.48
- REGN 97.87
About NSC Norfolk Southern Corporation
Class-I railroad Norfolk Southern operates in the Eastern United States. On more than 20,000 miles of track, the rail hauls shipments of coal, intermodal traffic, and a diverse mix of automotive, agriculture, metal, chemical, and forest products.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).